Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$114.5MMiss by $25.5M
EPS$0.19Miss by $0.00
Revenue estimate$140.0M
EPS estimate$0.19

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$125.3M
EPS estimate$0.16

Financials

Q1 2026

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$1.97B-54.3%
Enterprise value$2.03B-51.8%
P/E11.9×-8.7×
P/S3.9×-5.2×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Segments

By product

See full
ASCENIV$97.5M+27.7%
BIVIGAM$15.4M-54.0%
Intermediates And Other$833.0K-78.5%

By segment

See full
ADMA Bio Manufacturing$113.7M0.0%
Plasma Collection Centers$716.0K-31.8%

Versus estimates

Revenue

Q1 2026$114.5MMiss by $25.5M
Q4 2025$139.2MMiss by $437.0KQ3 2025$134.2MMiss by $5.6MQ2 2025$122.0MMiss by $8.3MQ1 2025$114.8MMiss by $7.0MQ4 2024$117.5MBeat by $8.9M

Diluted EPS

Q1 2026$0.19Miss by $0.00
Q4 2025$0.20Beat by $0.02Q3 2025$0.16In lineQ2 2025$0.15Beat by $0.01Q1 2025$0.14Miss by $0.02Q4 2024$0.14Miss by $0.01

Ask the moment ADMA Biologics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ADMA Biologics report Q1 2026 earnings?
ADMA Biologics (ADMA) reported Q1 2026 earnings on May 6, 2026 after market close.
What were ADMA Biologics's Q1 2026 revenue and EPS?
ADMA Biologics reported revenue of $114.5M and eps of $0.19 for Q1 2026.
Did ADMA Biologics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $140.0M by $25.5M. EPS missed the consensus estimate of $0.19 by $0.00.
How did ADMA Biologics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.3% from $114.8M a year earlier and eps grew 35.7% from $0.14.
Where can I find ADMA Biologics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001140361-26-018667) and the 10-Q periodic report (0001140361-26-019336) directly on SEC EDGAR. The filing index links above go to sec.gov.